UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023200
Receipt number R000026739
Scientific Title The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)
Date of disclosure of the study information 2016/09/01
Last modified on 2019/02/21 12:16:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)

Acronym

The study of aflibercept with treat and extend regimen for BRVO

Scientific Title

The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)

Scientific Title:Acronym

The study of aflibercept with treat and extend regimen for BRVO

Region

Japan


Condition

Condition

Branch retinal vein occlusion

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effectiveness of aflibercept for macular edema due to branch retinal vein occlusion (BRVO) in Japanese patients with prospective treatment regimen (Treat and Extend)

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

Change of BCVA from baseline to 12M

Key secondary outcomes

1. Change of OCT from baseline at 12M
2. The number of injections between 12M from baseline
3. Safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Eylea (aflibercept)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. more than 20 years-old, treatment-naive BRVO
2. Visual acuity : 0.1-0.5
3. The duration of BRVO < 3 months
4. outpatients

Key exclusion criteria

1. History of vitrectomy or glaucoma surgery
2. Other disorders such as DME, CRVO or idiopathic macular telangiectasia
3. Poor control hypertension (systolic pressure >180mmHg, diastolic pressure >100mmHg)
4. Concomitant conditions/diseases including uncontrolled glaucoma and intraocular inflammation
5. Patients who the doctor in charge judges are ineligible for the study

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masaaki Saito

Organization

Akita University

Division name

Department of Ophthalmology

Zip code


Address

44-2 Hasunua-Hiroomote, Akita city, Akita, Japan

TEL

018-834-1111

Email

masaaki@med.akita-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masaaki Saito

Organization

Akita University

Division name

Department of Ophthalmology

Zip code


Address

44-2 Hasunua-Hiroomote, Akita city, Akita, Japan

TEL

018-834-1111

Homepage URL


Email

masaaki@med.akita-u.ac.jp


Sponsor or person

Institute

Department of Ophthalmology, Akita University

Institute

Department

Personal name



Funding Source

Organization

Bayer Yakuhin Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Akita City Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 09 Month 01 Day

Date of IRB


Anticipated trial start date

2016 Year 10 Month 17 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 07 Month 16 Day

Last modified on

2019 Year 02 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026739


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name